OCU410ST employs an adeno-associated virus platform for retinal delivery of the RORA gene, targeting Stargardt disease ...

The OCU410ST Phase 2/3 pivotal confirmatory trial represents a major advancement as Ocugen's second late-stage clinical program. Ocugen plans to submit a BLA for OCU410ST in 2027 in alignment with its ...

In this Healio Video Perspective from the ARVO meeting, SriniVas R. Sadda, MD, FARVO, discusses a long-term study evaluating MCO-010 for the treatment of retinitis pigmentosa.

Retinitis pigmentosa (RP) is a group of genetic eye conditions that leads to incurable blindness.In the progression of symptoms for RP, night blindness generally precedes tunnel vision by years or ...

A breakthrough treatment has allowed damaged retinal cells to regenerate themselves. The current research has been conducted on mice, but the pathways are the same in humans, which opens hope for a ...

Nanoscope Therapeutics is on the brink of filing for FDA approval of what could be the first gene therapy for incurable eye disease retinitis pigmentosa (RP) that can be used regardless of ...

Nanoscope Therapeutics has reported data from a mid-stage clinical trial that suggests its optogenetic therapy based on light-sensitive molecules is an effective treatment for incurable eye ...

Significant advances have been made in the understanding of the genetics of retinitis pigmentosa (RP), a clinically and genetically heterogeneous group of disorders; ...

Total potential deal value of $110 million plus royaltiesKiora to receive an immediate $1.25 million exclusive option feeIf the option is exercised, Kiora will receive an additional mid-single ...

STGD Stargardt's Disease, PR pigmentosa retinitis, TE total energy, SFA saturated fats, MUFA monounsaturated fats, PUFA polyunstaurated fats, ...

After being diagnosed with retinitis pigmentosa at four, a condition that causes low vision, she lost most of her sight at 14. “I struggled a lot.